Skip to content
Smart Gamble 687

Individuals Coming Off Weight-Loss Medications Put On Pounds at a Quadrupled Rate Compared to Those on Conventional Diets

Image of medical injection and scale
Obesity treatment involves ongoing approaches.

New research indicates that patients who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise plans.

Published data in a major health publication points out that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.

"Individuals purchasing these medications need to be informed of the potential of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.

This pace of recovery implies a return to pre-treatment weight in about a year and a half.

Weighing Treatments

The analysis, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.

Scientists emphasize that individuals who lose weight through lifestyle changes alone generally experience a slower weight regain—approximately 100 grams monthly—once they finish.

Explaining the Fast Rebound

Doctors believe the mode of action of the drugs explains the heightened rebound.

These medications copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Long-term administration of the hormone concentrations far above than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating a significant risk."

A Chronic Condition?

The NHS recommend the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.

Professionals say that, due to the high risk of relapse, the therapy should be considered long-term.

This view is supported by drug manufacturers, who state that the findings "emphasize the chronic character of obesity," comparing it to managing conditions like diabetes.

User Experiences

People who have stopped the medication report a powerful resurgence of cravings.

"It felt as if something flipping and I was suddenly starving," said an individual.

This difficulty is worsened if patients have not established permanent dietary or behavioural changes during therapy.

Significant Interest

Recent estimates indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.

  • Adoption is more common among women compared to men.
  • The middle-aged age group shows the greatest usage rates.
  • Many access the drugs through private prescriptions rather than public health services.

In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss hinges on combined behavioural changes.

By

David Stevens

Maya Vance is a professional gambler and analyst with over a decade of experience in online betting and casino strategy development.

Smart Gamble 687

Type to search articles.